| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5586968 | Cytokine | 2017 | 8 Pages |
Abstract
A higher serum IL-17A level is a potential biomarker for predicting poor PFS in patients with HBV-related advanced HCC treated with sorafenib.
Keywords
IFN-γUICCEGFIP-10MCP-1FGFDNAHCCPFsalpha fetoproteindeoxyribonucleic acidinterferon-γinterleukinInterleukin-17AProgression free survivaloverall survivalstable diseaseprogressive diseaseAFPtumor necrosis factor-αSorafenibepidermal growth factorconfidence intervalgranulocyte colony-stimulating factorVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)fibroblast growth factorG-CSFTNF-αfibroblast growth factor-2hazard ratioHBVhepatitis B virusPartial responsemonocyte chemoattractant protein-1prognosisHepatocellular carcinoma
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Hyo Jung Cho, Soon Sun Kim, Ji Sun Nam, Min Jung Oh, Dae Ryong Kang, Jai Keun Kim, Jei Hee Lee, Bohyun Kim, Min Jae Yang, Jae Chul Hwang, Sun Gyo Lim, Sung Jae Shin, Kee Myung Lee, Byung Moo Yoo, Kwang Jae Lee, Sung Won Cho, Jae Youn Cheong,